Yuan R, McGeehan A, Zhou S, Cheng C, et al. The anti-FRalpha antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell death. Mol Cancer Ther 2025 Apr 28. doi: 10.1158/1535-7163.MCT-24-0649.
PMID: 40293943